U.S. markets open in 8 hours 7 minutes

AtriCure, Inc. (ATRC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
65.90-0.63 (-0.95%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Ascending Continuation Triangle

Ascending Continuation Triangle

Previous Close66.53
Open66.63
Bid0.00 x 800
Ask0.00 x 800
Day's Range64.60 - 66.84
52 Week Range34.04 - 68.00
Volume215,793
Avg. Volume387,640
Market Cap3.007B
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-1.14
Earnings DateApr 27, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AtriCure Names B. Kristine Johnson Board Chair
    Business Wire

    AtriCure Names B. Kristine Johnson Board Chair

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair. In addition, the Company announced that Scott Drake and Mark Lanning will not stand for re-election at the end of their terms in May 2021.

  • AtriCure to Announce First Quarter 2021 Financial Results
    Business Wire

    AtriCure to Announce First Quarter 2021 Financial Results

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021.

  • AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference
    Business Wire

    AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference.